Natera, Inc. (NTRA) Cash Flow Statement

The persistent gap between net income and operating cash flow is driven by substantial stock-based compensation, which averaged over $90M per quarter in recent periods. This suggests that while GAAP profitability remains elusive, the underlying cash-generating ability of the business is stronger than the income statement implies. Investors should monitor whether this divergence narrows as SBC growth moderates.

The trajectory shows improving FCF margins from -1.9% in 2024Q2 to 2.6% in 2026Q1, though 2026Q2 dipped to -1.1% due to elevated capex. This suggests that operating leverage is beginning to materialize as oncology volumes scale, but the sustainability depends on controlling capex intensity. The positive FCF in two of the last three quarters is a notable improvement over the prior year's negative readings.

The sharp increase in capex suggests management is investing in laboratory automation and capacity to support the record oncology volumes. While this temporarily pressures FCF, it may indicate a bet on future growth. The capital intensity remains moderate relative to peers, but investors should watch whether this elevated spending persists and translates into higher gross margins.

The volatility in working capital is likely tied to the timing of insurance reimbursements and the transition to accrual-based revenue recognition. The large negative swing in 2025Q4 suggests a significant cash outflow from receivables, while the positive swing in 2025Q3 indicates strong collections. This pattern underscores the need to analyze cash flow over multiple quarters rather than a single period.

The absence of shareholder returns is consistent with a growth-stage company prioritizing internal investment. The $16.0M acquisition in 2025Q4 indicates selective M&A, but the primary use of cash is funding expansion. Given the positive FCF in recent quarters, management may eventually consider capital returns, but the focus appears to be on scaling the oncology franchise.

The cumulative gap between net income and operating cash flow is primarily attributable to stock-based compensation, which totaled over $800M in the period. This suggests that the company's cash burn is far less severe than GAAP losses imply, and the business is approaching cash flow break-even. However, the reliance on SBC to bridge the gap raises questions about dilution and the true cost of employee compensation.